Mercer Global Advisors
CRBP icon

Mercer Global Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Mercer Global Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,058
Closed -$4K – 1952
2022
Q4 		$4K Hold
1,058
– – ﹤0.01% 1922
2022
Q3 		$5K Hold
1,058
– – ﹤0.01% 1813
2022
Q2 		$8K Sell
1,058
-19
-2% -$184 ﹤0.01% 1813
2022
Q1 		$17K Buy
+1,077
New +$14.3K ﹤0.01% 1856

Other funds holding CRBP

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Mercer Global Advisors's CRBP Position: Q1 2023 in Review

Mercer Global Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q1 2023, closing a stake of 1,058 shares — an estimated $4K sold.

Mercer Global Advisors first reported a position in CRBP in Q1 2022 and held it in 4 quarters. The position peaked at $17K in Q1 2022. 30 funds tracked by Wall St. Rank hold CRBP as of Q1 2023.

  • Mercer Global Advisors reported no remaining Corbus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Mercer Global Advisors sold 1,058 Corbus Pharmaceuticals shares in Q1 2023, an estimated $4K.
  • Mercer Global Advisors first reported a position in Corbus Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Mercer Global Advisors's Corbus Pharmaceuticals position peaked at $17K in Q1 2022.
  • 30 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2023.

Based on Mercer Global Advisors's 13F filing for Q1 2023, filed 16 May 2023.